The biosimilar contract manufacturing market is on the cusp of transformative growth, driven by the escalating demand for cost-effective biopharmaceuticals and the strategic shift toward outsourcing among global pharma giants. According to the latest comprehensive analysis, the market, valued at USD 8.9 billion in 2025, is forecasted to expand at a robust compound annual growth rate...